Q&A: What does COVID-19 antiviral treatment look like in 2023?
Co-chair of the COVID-19 clinical evidence taskforce discusses emerging treatments and the taskforce’s uncertain future
This content has been independently produced by ADG, made possible through sponsorship from Gilead.
In this Q&A, infectious disease physician Professor Josh Davis speaks to ADG about COVID-19 antivirals, both old and new, long COVID challenges, and the reasons molnupiravir (Lagevrio) was downgraded to a last-resort treatment by the National Clinical Evidence Taskforce.
